Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Amicus Therapeutics, Inc. (NASDAQ:FOLD) securities between March 19, 2015 and October 1, 2015.
Click here to learn about the case: http://docs.wongesq.com/FOLD-Info-Request-Form-939. There is no cost or obligation to you.
The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics’ forthcoming new drug application for migalastat during their September 15, 2015 meeting.
On October 2, 2015, Amicus Therapeutics revealed it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Upon this news, shares of Amicus Therapeutics fell 54% to close at $6.39 per share.
If you suffered a loss in Amicus Therapeutics you have until December 7, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/FOLD-Info-Request-Form-939.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
